Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Characteristics of Multiple Sclerosis Patients by Phenotype: A Cross-Sectional Analysis Using the CLIMB Study
Multiple Sclerosis
P5 - Poster Session 5 (11:45 AM-12:45 PM)
3-006
MS is categorized into phenotypes based on its clinical course. Understanding how characteristics vary across phenotype, and how characteristics change at the time of phenotype transition is of interest, as treatment intervention at, or prior to this stage, may impact long-term treatment outcomes. 

To investigate how multiple sclerosis (MS) prevalence and characteristics vary across different MS phenotypes within the Comprehensive Longitudinal Investigation of MS at the Brigham and Women’s Hospital (CLIMB) Study. 

Retrospective analysis of the US-based CLIMB Study identified people with MS (pwMS) (aged 18-65y), and stratified them based on phenotype at “index” (Dec-22-2021): relapsing-remitting MS [RRMS], primary-progressive MS [PPMS], active secondary-progressive MS [aSPMS], non-relapsing secondary-progressive MS [nrSPMS]. Demographics were extracted alongside disability scores (Expanded Disability Status Scale [EDSS]). Between-group differences were calculated using chi-square (categorical variables) or Kruskal-Wallis by ranks (continuous variables) tests. Data are presented mean±SD.
The analyzed cohort (n=2,599 pwMS) included: RRMS, n=1,891[72.8%]; PPMS, n=133[5.1%]; nrSPMS, n=534[20.5%]; aSPMS, n=41[1.6%] patients. Overall, 46.6%-75.9% of cohorts were female. Age at MS onset was lower for aSPMS (32.2±12.7y), RRMS (32.6±9.7y), and nrSPMS (33.8±10.4y) vs. PPMS (44.4±10.7y; P<0.001). Disease duration (at index) ranged from 16.2±9.9y (RRMS) to 26.1±11.8y (nrSPMS). RRMS patients had a shorter duration to first treatment vs. other phenotypes (4.2y vs. 7.2-9.4y; P<0.001). The majority of aSPMS (61.0%) and RRMS (68.7%) patients were receiving disease-modifying therapies (DMTs) at index vs. nrSPMS (58.2%) and PPMS (51.9%). EDSS scores were higher for nrSPMS (5.9±1.8), PPMS (5.9±1.8), and aSPMS (5.7±1.9), than for RRMS (1.9±1.5; P<0.001).

Among pwMS in the United States identified in this cohort, 20.5% had nrSPMS. Characteristics varied by phenotype, with nrSPMS and PPMS patients waiting longer for first treatment and being less likely to be on DMTs, despite higher disability burden vs. RRMS patients. This highlights an unmet clinical need among patients with progressive MS.

Authors/Disclosures
Gauruv Bose, MD (The University of Ottawa and Ottawa Hospital Research Institute)
PRESENTER
Dr. Bose has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Bose has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Bose has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Teva Pharmaceuticals. The institution of Dr. Bose has received research support from Multiple Sclerosis Society of Canada.
Nupur Greene Nupur Greene has nothing to disclose.
Brian Curran Healy The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Howard L. Weiner, MD (Brigham and Women'S Hospital) Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Weiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Tiziana Life Sciences. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for vTv Therapeutics. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medday Pharmaceuticals. Dr. Weiner has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for vTv Therapeutics. Dr. Weiner has stock in vTv Therapeutics. The institution of Dr. Weiner has received research support from National Institute of Health. The institution of Dr. Weiner has received research support from National MS Society. The institution of Dr. Weiner has received research support from Genzyme Corp. The institution of Dr. Weiner has received research support from Genentech, Inc. . The institution of Dr. Weiner has received research support from Verily Life Sciences LLC. The institution of Dr. Weiner has received research support from EMD Serono, Inc..
Lisa E. Farnett (Sanofi) Ms. Farnett has received personal compensation for serving as an employee of Sanofi. Ms. Farnett has stock in Sanofi.
Keiko Higuchi, Other (SANOFI genzyme) Miss Higuchi has received personal compensation for serving as an employee of Sanofi. Miss Higuchi has received personal compensation for serving as an employee of Novartis. Miss Higuchi has received personal compensation for serving as an employee of Gilead Sciences . Miss Higuchi has received personal compensation for serving as an employee of Pfizer Inc. . Miss Higuchi has received personal compensation for serving as an employee of Zynx Health Inc. . Miss Higuchi has received stock or an ownership interest from Sanofi. Miss Higuchi has received stock or an ownership interest from Gilead. Miss Higuchi has received stock or an ownership interest from Novartis.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital) Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Siemens. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Academic CME. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche.